Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro

FEBS Letters

Volumn 581, Issue 5, 2007, Pages 1067-1070

  Rashid, Imran ^a   van Reyk, David M ^b   Davies, Michael J ^a,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c University of Sydney   (Australia)

Author keywords

Aldehyde; Atherosclerosis; Carnosine; Foam cell; Glycation; Low density lipoprotein

Indexed keywords

ALDEHYDE DERIVATIVE; BETA ALANINE; CARNOSINE; HISTIDINE; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FOAM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

BETA-ALANINE; CARDIOVASCULAR DISEASES; CARNOSINE; DIABETIC ANGIOPATHIES; FOAM CELLS; GLYCOSYLATION; HISTIDINE; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES;

EID: 33847222132     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.01.082     Document Type: Article

References (31)

1. Khaw K.-T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the european prospective investigation into cancer in norfolk. Ann. Intern. Med. 141 (2004) 413-420
2. Wei M., Gaskill S.P., Haffner S.M., and Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21 (1998) 1167-1172
3. DCCT/EDIC. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Eng. J. Med. 353 (2005) 2643-2653
4. Lo T.W.C., Westwood M.E., McLellan A.C., Selwood T., and Thornalley P.J. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nα-acetylarginine, Nα-acetylcysteine, and Nα-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269 (1994) 32299-32305
5. McClellan A.C., Thornalley P.J., Benn J., and Sonksen P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. 87 (1994) 21-29
6. Odani H., Shinzato T., Matsumoto Y., Usami J., and Maeda K. Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 256 (1999) 89-93
7. Lapolla A., Flamini R., dalla Vedova A., Senesi A., Reitano R., Fedele D., Basso E., Seraglia R., and Traldi P. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin. Chem. Lab. Med. 41 (2003) 1166-1173
8. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Prac. 67 (2005) 3-12
9. Wolff S.P., and Dean R.T. Glucose autoxidation and protein modification. The potential role of autoxidative glycosylation in diabetes. Biochem. J. 245 (1987) 243-250
10. Rashid I., Brown B.E., van Reyk D.M., and Davies M.J. The roles of glycation and glycoxidation and advanced glycation end product formation in diabetes-induced atherosclerosis. In: Cheema S.K. (Ed). Biochemistry of Atherosclerosis (2006), Springer Verlag, New York 247-283
11. Brown B.E., Mahroof F.M., Cook N.L., van Reyk D.M., and Davies M.J. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 49 (2006) 775-783
12. Brown B.E., Dean R.T., and Davies M.J. Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 48 (2005) 361-369
13. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8 (2002) 1235-1242
14. Park Y.J., Volpe S.L., and Decker E.A. Quantitation of carnosine in humans plasma after dietary consumption of beef. J. Agric. Food Chem. 53 (2005) 4736-4739
15. Maynard L.M., Boissonneault G.A., Chow C.K., and Bruckner G.G. High levels of dietary carnosine are associated with increased concentrations of carnosine and histidine in rat soleus muscle. J. Nutr. 131 (2001) 287-290
16. Hipkiss A.R., and Brownson C. A possible new role for the anti-ageing peptide carnosine. Cell Mol. Life Sci. 57 (2000) 747-753
17. Guiotto A., Calderan A., Ruzza P., and Borin G. Carnosine and carnosine-related antioxidants: a review. Curr. Med. Chem. 12 (2005) 2293-2315
18. Janssen B., Hohenadel D., Brinkkoetter P., Peters V., Rind N., Fischer C., Rychlik I., Cerna M., Romzova M., de Heer E., Baelde H., Bakker S.J.L., Zirie M., Rondeau E., Mathieson P., Saleem M.A., Meyer J., Koppel H., Sauerhoefer S., Bartram C.R., Nawroth P., Hammes H.-P., Yard B.A., Zschocke J., and van der Woude F.J. Carnosine as a protective factor in diabetic nephropathy. Association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54 (2005) 2320-2327
19. Knott H.M., Brown B.E., Davies M.J., and Dean R.T. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur. J. Biochem. 270 (2003) 3572-3582
20. Garner B., Dean R.T., and Jessup W. Human macrophage-mediated oxidation of low-density lipoprotein is delayed and independent of superoxide production. Biochem. J. 301 (1994) 421-428
21. Chung B.H., Segrest J.P., Ray M.J., Brunzell J.D., Hokanson J.E., Kraus R.M., Beaudrie K., and Cone J.T. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 128 (1986) 181-209
22. Lee Y.-T., Hsi C.-C., Lin M.-H., Liu K.-S., and Yimn M.-C. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur. J. Pharmacol. 513 (2005) 145-150
23. Lenney J.F., George R.P., Weiss A.M., Kucera C.M., Chan P.W.H., and Rinzler G.S. Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. Clin. Chim. Acta 123 (1982) 221-231
24. Zhou S., and Decker E.A. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J. Agric. Food Chem. 47 (1999) 51-55
25. Aldini G., Granata P., and Carini M. Detoxification of cytotoxic α,β-unsaturated aldehydes by carnosine: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J. Mass Spectrom. 37 (2002) 1219-1228
26. Ukeda H., Hasegawa Y., Harada Y., and Sawamura M. Effect of carnosine and related compounds on the inactivation of human Cu,Zn-superoxide dismutase by modification of fructose and glycolaldehyde. Biosci. Biotech. Biochem. 66 (2002) 36-43
27. Aldini G., Carini M., Beretta G., Bradamante S., and Maffei Facino R. Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction?. Biochem. Biophys. Res. Commun. 298 (2002) 699-706
28. Hobart L.J., Seibel I., Yeargans G.S., and Seidler N.W. Anti-crosslinking properties of carnosine: significance of histidine. Life Sci. 75 (2004) 1379-1389
29. Zhang H., Yang Y., and Steinbrecher U.P. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J. Biol. Chem. 268 (1993) 5535-5542
30. Gardner M.L.G., Illingworth K.M., Kelleher J., and Wood D. Intestinal absorption of the intact peptide carnosine in man, and comparison with intestinal permeability to lactulose. J. Physiol. 439 (1991) 411-422
31. Brown, B.E., Rashid, I., van Reyk, D.M., Davies, M.J. (2007). Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J., in press.